Regeneron Pharmaceuticals Inc. (REGN): Today's Featured Drugs Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Regeneron Pharmaceuticals ( REGN) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day down 0.6%. By the end of trading, Regeneron Pharmaceuticals fell $6.31 (-2.0%) to $300.80 on heavy volume. Throughout the day, 1,622,190 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 708,800 shares. The stock ranged in price between $299.11-$307.00 after having opened the day at $306.81 as compared to the previous trading day's close of $307.11. Other companies within the Drugs industry that declined today were: Prosensa Holding N.V ( RNA), down 70.2%, Imprimis Pharmaceuticals ( IMMY), down 13.5%, Ohr Pharmaceutical ( OHRP), down 12.9% and ProPhase Labs ( PRPH), down 11.6%.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. Regeneron Pharmaceuticals has a market cap of $28.7 billion and is part of the health care sector. Shares are up 80.7% year to date as of the close of trading on Thursday. Currently there are 10 analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Regeneron Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, solid stock price performance and increase in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.

On the positive front, GW Pharmaceuticals PLC ADR ( GWPH), up 69.3%, Verenium Corporation ( VRNM), up 58.2%, Cyclacel Pharmaceuticals ( CYCC), up 24.7% and Sarepta Therapeutics ( SRPT), up 18.0% , were all gainers within the drugs industry with Endo Health Solutions ( ENDP) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.